Key statistics
On Friday, Centessa Pharmaceuticals PLC (CNTA:NSQ) closed at 24.71, -19.20% below its 52-week high of 30.58, set on Dec 08, 2025.
52-week range
| Open | 24.29 |
|---|---|
| High | 25.80 |
| Low | 24.07 |
| Bid | 22.00 |
| Offer | 27.90 |
| Previous close | 24.25 |
| Average volume | 1.24m |
|---|---|
| Shares outstanding | 146.05m |
| Free float | 132.95m |
| P/E (TTM) | -- |
| Market cap | 3.54bn USD |
| EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
- Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
- Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
- Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
- Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
More ▼
